Gemcitabine

Generic Name
Gemcitabine
Brand Names
Gemzar
Drug Type
Small Molecule
Chemical Formula
C9H11F2N3O4
CAS Number
95058-81-4
Unique Ingredient Identifier
B76N6SBZ8R
Background

Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication

Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions
Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

First Posted Date
2023-10-26
Last Posted Date
2024-11-25
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
252
Registration Number
NCT06102824
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

First Posted Date
2023-10-13
Last Posted Date
2024-12-12
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
376
Registration Number
NCT06081959
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

First Posted Date
2023-10-12
Last Posted Date
2023-10-12
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Target Recruit Count
108
Registration Number
NCT06080854
Locations
🇨🇳

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

First Posted Date
2023-10-03
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT06064097
Locations
🇺🇸

Lurie Children's Hospital-Chicago, Chicago, Illinois, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 40 locations

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered Iv in Patients with PDAC

First Posted Date
2023-09-28
Last Posted Date
2024-11-18
Lead Sponsor
Peptomyc S.L.
Target Recruit Count
30
Registration Number
NCT06059001
Locations
🇪🇸

Hospital Regional Universitario de Málaga, Málaga, Spain

🇪🇸

Hospital Universitario Marqués de Valdecilla, Santander, Spain

🇪🇸

ICO Hopsitalet, L´Hospitalet de Llobregat, Barcelona, Spain

and more 3 locations

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

First Posted Date
2023-09-26
Last Posted Date
2023-09-26
Lead Sponsor
Biocity Biopharmaceutics Co., Ltd.
Target Recruit Count
112
Registration Number
NCT06055348

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

First Posted Date
2023-09-25
Last Posted Date
2023-09-25
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Target Recruit Count
177
Registration Number
NCT06051851
Locations
🇨🇳

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

First Posted Date
2023-09-22
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
27
Registration Number
NCT06050252
Locations
🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

UCHealth University of Colorado Hospital, Aurora, Colorado, United States

and more 39 locations

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

First Posted Date
2023-09-21
Last Posted Date
2024-08-02
Lead Sponsor
Nataliya Uboha
Target Recruit Count
39
Registration Number
NCT06048133
Locations
🇺🇸

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 1 locations

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

First Posted Date
2023-09-18
Last Posted Date
2023-09-18
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
115
Registration Number
NCT06041035
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy